$PTCT
PTC Therapeutics Inc

2021 Q3 Form 10-Q Financial Statement

#000107008121000029 Filed on July 29, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $138.7M $116.7M $75.24M
YoY Change 17.18% 55.07% -12.02%
Cost Of Revenue $6.539M $7.358M $5.300M
YoY Change 39.13% 38.83% 65.06%
Gross Profit $132.2M $109.3M $69.90M
YoY Change 16.27% 56.39% -15.08%
Gross Profit Margin 95.29% 93.69% 92.9%
Selling, General & Admin $69.25M $68.88M $53.66M
YoY Change 19.73% 28.36% 9.03%
% of Gross Profit 52.38% 63.01% 76.77%
Research & Development $130.8M $125.5M $176.5M
YoY Change 40.7% -28.92% 194.31%
% of Gross Profit 98.97% 114.79% 252.54%
Depreciation & Amortization $16.75M $14.98M $10.21M
YoY Change 43.9% 46.75% 32.6%
% of Gross Profit 12.67% 13.71% 14.61%
Operating Expenses $231.8M $215.2M $262.5M
YoY Change 33.59% -18.03% 111.23%
Operating Profit -$93.08M -$98.49M -$187.3M
YoY Change 68.83% -47.41% 383.19%
Interest Expense -$21.80M -$22.56M -$5.379M
YoY Change 3.63% 319.39% 159.35%
% of Operating Profit
Other Income/Expense, Net -$18.78M $3.170M $11.31M
YoY Change -165.29% -71.97% -6279.78%
Pretax Income -$133.7M -$117.9M -$181.3M
YoY Change 181.96% -35.0% 342.14%
Income Tax -$36.00K $488.0K $84.00K
% Of Pretax Income
Net Earnings -$133.6M -$118.4M -$181.4M
YoY Change 91.74% -34.76% 334.15%
Net Earnings / Revenue -96.31% -101.45% -241.13%
Basic Earnings Per Share -$1.89 -$1.68
Diluted Earnings Per Share -$1.893M -$1.68 -$2.782M
COMMON SHARES
Basic Shares Outstanding 70.60M 70.41M 62.88M shares
Diluted Shares Outstanding 70.59M 70.41M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $867.9M $947.1M $498.9M
YoY Change -23.93% 89.83% 37.25%
Cash & Equivalents $189.8M $177.3M $158.5M
Short-Term Investments $678.1M $769.7M $340.4M
Other Short-Term Assets $30.94M $23.91M $34.10M
YoY Change 15.01% -29.88% 95.98%
Inventory $15.61M $16.44M $18.37M
Prepaid Expenses
Receivables $96.65M $78.80M $53.60M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.011B $1.066B $605.0M
YoY Change -18.73% 76.23% 27.38%
LONG-TERM ASSETS
Property, Plant & Equipment $46.35M $42.91M $26.81M
YoY Change 64.72% 60.08% 74.17%
Goodwill $82.34M $82.34M $82.30M
YoY Change 0.05% 0.05% 0.0%
Intangibles $723.3M $717.1M $708.8M
YoY Change 1.51% 1.17% 0.87%
Long-Term Investments
YoY Change
Other Assets $65.53M $69.41M $48.80M
YoY Change 133.21% 42.24% 741.38%
Total Long-Term Assets $996.2M $992.4M $871.6M
YoY Change 6.33% 13.86% 6.74%
TOTAL ASSETS
Total Short-Term Assets $1.011B $1.066B $605.0M
Total Long-Term Assets $996.2M $992.4M $871.6M
Total Assets $2.007B $2.059B $1.477B
YoY Change -7.97% 39.42% 14.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $21.46M $20.82M $15.47M
YoY Change 37.02% 34.63% 51.34%
Accrued Expenses $82.05M $76.58M $51.10M
YoY Change 20.66% 49.86% 43.14%
Deferred Revenue $0.00 $7.702M
YoY Change -100.0% -3.79%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $149.4M $46.46M $18.33M
YoY Change 153.4% -8.34%
Total Short-Term Liabilities $465.3M $291.0M $201.8M
YoY Change 83.3% 44.15% 16.03%
LONG-TERM LIABILITIES
Long-Term Debt $281.6M $430.5M $297.0M
YoY Change -7.05% 44.93% 118.91%
Other Long-Term Liabilities $1.376M $1.392M $26.68M
YoY Change -30.08% -94.78% 216.99%
Total Long-Term Liabilities $283.0M $431.9M $323.7M
YoY Change -7.2% 33.42% 124.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $465.3M $291.0M $201.8M
Total Long-Term Liabilities $283.0M $431.9M $323.7M
Total Liabilities $1.902B $1.862B $904.1M
YoY Change 13.91% 105.95% 12.61%
SHAREHOLDERS EQUITY
Retained Earnings -$1.955B -$1.821B -$1.485B
YoY Change 25.74% 22.65% 41.03%
Common Stock $70.00K $70.00K $67.00K
YoY Change 2.94% 4.48% 15.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $104.9M $196.6M $572.5M
YoY Change
Total Liabilities & Shareholders Equity $2.007B $2.059B $1.477B
YoY Change -7.97% 39.42% 14.33%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$133.6M -$118.4M -$181.4M
YoY Change 91.74% -34.76% 334.15%
Depreciation, Depletion And Amortization $16.75M $14.98M $10.21M
YoY Change 43.9% 46.75% 32.6%
Cash From Operating Activities -$51.19M -$31.14M -$74.81M
YoY Change -292.08% -58.37% 145.12%
INVESTING ACTIVITIES
Capital Expenditures -$5.844M -$7.973M -$2.160M
YoY Change 76.56% 269.12% 9.09%
Acquisitions
YoY Change
Other Investing Activities $70.55M $64.03M $144.2M
YoY Change -118.05% -55.6% -498.51%
Cash From Investing Activities $64.70M $56.05M $142.1M
YoY Change -116.41% -60.54% -472.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.976M 4.017M -32.92M
YoY Change -99.54% -112.2% -1255.09%
NET CHANGE
Cash From Operating Activities -51.19M -31.14M -74.81M
Cash From Investing Activities 64.70M 56.05M 142.1M
Cash From Financing Activities 2.976M 4.017M -32.92M
Net Change In Cash 16.49M 28.93M 34.32M
YoY Change -94.01% -15.71% -152.13%
FREE CASH FLOW
Cash From Operating Activities -$51.19M -$31.14M -$74.81M
Capital Expenditures -$5.844M -$7.973M -$2.160M
Free Cash Flow -$45.35M -$23.17M -$72.65M
YoY Change -251.36% -68.11% 154.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001070081
dei Amendment Flag
AmendmentFlag
false
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70559330
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69718096
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P6M
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35969
dei Entity Registrant Name
EntityRegistrantName
PTC Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3416587
dei Entity Address Address Line1
EntityAddressAddressLine1
100 Corporate Court
dei Entity Address City Or Town
EntityAddressCityOrTown
South Plainfield,
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07080
dei City Area Code
CityAreaCode
908
dei Local Phone Number
LocalPhoneNumber
222-7000
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
PTCT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
70604925
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
177347000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
208812000
CY2021Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
769734000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
894838000
CY2021Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
78801000
CY2020Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
69929000
CY2021Q2 us-gaap Inventory Net
InventoryNet
16441000
CY2020Q4 us-gaap Inventory Net
InventoryNet
18697000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
23910000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
39469000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
1066233000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
1231745000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42910000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33831000
CY2021Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
717079000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
715328000
CY2021Q2 us-gaap Goodwill
Goodwill
82341000
CY2020Q4 us-gaap Goodwill
Goodwill
82341000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
80694000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
84410000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69718096
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
70000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
70000
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2063687000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2171746000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-46087000
CY2021Q2 ptct Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
69412000
CY2020Q4 ptct Deposits And Other Assets Noncurrent
DepositsAndOtherAssetsNoncurrent
60623000
CY2021Q2 us-gaap Assets
Assets
2058669000
CY2020Q4 us-gaap Assets
Assets
2208278000
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
235921000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
242168000
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4151000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7335000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7465000
CY2021Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2121000
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1276000
CY2021Q2 ptct Liability Sale Of Future Royalties Current
LiabilitySaleOfFutureRoyaltiesCurrent
44335000
CY2020Q4 ptct Liability Sale Of Future Royalties Current
LiabilitySaleOfFutureRoyaltiesCurrent
21023000
CY2021Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1250000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1250000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
290962000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
277333000
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
430496000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
309145000
CY2021Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
241200000
CY2020Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
240400000
CY2021Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
136735000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
136735000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
76425000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
79499000
CY2021Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
20053000
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
23053000
CY2021Q2 ptct Liability Sale Of Future Royalties Noncurrent
LiabilitySaleOfFutureRoyaltiesNoncurrent
664829000
CY2020Q4 ptct Liability Sale Of Future Royalties Noncurrent
LiabilitySaleOfFutureRoyaltiesNoncurrent
658739000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1392000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1392000
CY2021Q2 us-gaap Liabilities
Liabilities
1862092000
CY2020Q4 us-gaap Liabilities
Liabilities
1726296000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70559330
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-60957000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1821093000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1628877000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
196577000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
481982000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2058669000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2208278000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
116676000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
75239000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
234620000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
143498000
CY2021Q2 ptct Costof Goodsand Service Excluding Amortization Of Intangible Assets
CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets
7358000
CY2020Q2 ptct Costof Goodsand Service Excluding Amortization Of Intangible Assets
CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets
5304000
ptct Costof Goodsand Service Excluding Amortization Of Intangible Assets
CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets
16462000
ptct Costof Goodsand Service Excluding Amortization Of Intangible Assets
CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets
9389000
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12751000
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8731000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24028000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
16679000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
125482000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
176525000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
259995000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
266632000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
68878000
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
53659000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
129973000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
111869000
CY2021Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-700000
CY2020Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-7680000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-800000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-8580000
CY2021Q2 ptct Settlement Of Deferred And Contingent Consideration
SettlementOfDeferredAndContingentConsideration
0
CY2020Q2 ptct Settlement Of Deferred And Contingent Consideration
SettlementOfDeferredAndContingentConsideration
10613000
ptct Settlement Of Deferred And Contingent Consideration
SettlementOfDeferredAndContingentConsideration
10613000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
215169000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
262512000
us-gaap Operating Expenses
OperatingExpenses
431258000
us-gaap Operating Expenses
OperatingExpenses
423762000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-98493000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-187273000
us-gaap Operating Income Loss
OperatingIncomeLoss
-196638000
us-gaap Operating Income Loss
OperatingIncomeLoss
-280264000
CY2021Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-22559000
CY2020Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-5379000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-41718000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-11021000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3170000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11309000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7716000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2523000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-117882000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-181343000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-246072000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-293808000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
488000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
84000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
940000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
306000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-118370000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-181427000
us-gaap Net Income Loss
NetIncomeLoss
-247012000
us-gaap Net Income Loss
NetIncomeLoss
-294114000
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
70414632
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
65150780
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
70302241
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
63769958
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.68
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.78
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.51
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.61
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-118370000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-181427000
us-gaap Net Income Loss
NetIncomeLoss
-247012000
us-gaap Net Income Loss
NetIncomeLoss
-294114000
us-gaap Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
0
CY2020Q2 us-gaap Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
0
CY2021Q2 us-gaap Other Comprehensive Income Availableforsale Securities Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent
0
CY2021Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-75000
CY2020Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2718000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1369000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2655000
us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-7269000
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-10749000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
16239000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2087000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-125714000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-189458000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-232142000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-293546000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
292576000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1389000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2627000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25699000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-118370000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-7344000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
196577000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
528734000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5447000
CY2020Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
42869000
CY2020Q2 ptct Stock Issued During Period Value Exchange Rights
StockIssuedDuringPeriodValueExchangeRights
150528000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15058000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2406000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16910000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-181427000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-8031000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
572494000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
481982000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13144000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2627000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
51406000
us-gaap Net Income Loss
NetIncomeLoss
-247012000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
14870000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
196577000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
594330000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18950000
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
42869000
ptct Stock Issued During Period Value Exchange Rights
StockIssuedDuringPeriodValueExchangeRights
150528000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
25045000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2406000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32130000
us-gaap Stockholders Equity Other
StockholdersEquityOther
218000
us-gaap Net Income Loss
NetIncomeLoss
-294114000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
568000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
572494000
us-gaap Net Income Loss
NetIncomeLoss
-247012000
us-gaap Net Income Loss
NetIncomeLoss
-294114000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
28573000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19445000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3666000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2401000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
41212000
ptct Noncash Royalty Revenue Sale Of Future Royalties
NoncashRoyaltyRevenueSaleOfFutureRoyalties
8681000
ptct Noncash Interest Expense Liability Related To Sale Of Future Royalties
NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties
38083000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
800000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
8580000
ptct Settlement Of Deferred And Contingent Consideration
SettlementOfDeferredAndContingentConsideration
10613000
ptct Shares Issued Asset Acquisition
SharesIssuedAssetAcquisition
42869000
ptct Clearpoint Equity Investment Fvni Unrealized Gain Loss
ClearpointEquityInvestmentFvniUnrealizedGainLoss
4110000
ptct Clearpoint Equity Investment Fvni Unrealized Gain Loss
ClearpointEquityInvestmentFvniUnrealizedGainLoss
-1600000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
4326000
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
-749000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
694000
us-gaap Paid In Kind Interest
PaidInKindInterest
10993000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-26000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2644000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
635000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
911000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
510000
us-gaap Share Based Compensation
ShareBasedCompensation
51406000
us-gaap Share Based Compensation
ShareBasedCompensation
32130000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-15983000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
3248000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1906000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-943000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-15649000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
16569000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
9420000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-1860000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
289000
us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
175000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-9223000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-7497000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-3083000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-4132000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4085000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3925000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-131302000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-156364000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13643000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8183000
ptct Payments To Acquire Convertible Debt Investment
PaymentsToAcquireConvertibleDebtInvestment
10000000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
192931000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
367102000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
200000000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
514716000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
428490000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
21838000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2422000
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
100000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
86204000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
40783000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
13144000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
25045000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18950000
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
10000000
ptct Payments On Deferred Consideration Obligation
PaymentsOnDeferredConsiderationObligation
35829000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2627000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2406000
ptct Payment Of Finance Lease Principal
PaymentOfFinanceLeasePrincipal
2224000
ptct Payment Of Finance Lease Principal
PaymentOfFinanceLeasePrincipal
15000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13547000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-14428000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
442000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31465000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-129567000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
216312000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
295528000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
184847000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
165961000
us-gaap Interest Paid Net
InterestPaidNet
5182000
us-gaap Interest Paid Net
InterestPaidNet
5286000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4127000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1140000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-1369000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
2655000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
13000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
18117000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
41212000
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
18369000
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
12186000
ptct Stock Issued During Period Value Exchange Rights
StockIssuedDuringPeriodValueExchangeRights
150528000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.        The Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">PTC Therapeutics, Inc. (the “Company” or “PTC”) is a science-driven global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company’s ability to globally commercialize products is the foundation that drives its continued investment in a robust diversified pipeline of transformative medicines and its mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company’s strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has two products, Translarna™ (ataluren) and Emflaza™ (deflazacort), for the treatment of Duchenne muscular dystrophy (“DMD”), a rare, life threatening disorder. Translarna has marketing authorization in the European Economic Area (the “EEA”) for the treatment of nonsense mutation Duchenne muscular dystrophy (“nmDMD”) in ambulatory patients aged 2 years and older and in Brazil for the treatment of nmDMD in ambulatory patients aged 5 years and older, subject to annual renewal and other conditions. In July 2020, the European Commission approved the removal of the statement “efficacy has not been demonstrated in non-ambulatory patients” from the indication statement for Translarna. Emflaza is approved in the United States for the treatment of DMD in patients two years and older.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company holds the rights for the commercialization of Tegsedi™ (inotersen) and Waylivra™ (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to the Collaboration and License Agreement (the “Akcea Collaboration and License Agreement”), dated August 1, 2018, by and between the Company and Akcea Therapeutics, Inc. (“Akcea”). Tegsedi has received marketing authorization in the United States, the European Union (the “EU”) and Brazil for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (“hATTR amyloidosis”). While the Company is in the process of initiating its<span style="background-color:#ffffff;"> commercial launch for Tegsedi for the treatment of hATTR amyloidosis in Latin America, it continues to make Tegsedi available in certain countries within Latin America and the Caribbean through early access programs. </span>Waylivra has received marketing authorization in the EU for the treatment of familial chylomicronemia syndrome (“FCS”). The Company filed for marketing authorization for Waylivra for the treatment of FCS with ANVISA, the Brazilian health regulatory authority, in June 2020 and, subject to further potential delays in the review process related to the COVID-19 pandemic, expects a regulatory decision on approval from ANVISA in the fourth quarter of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also has a spinal muscular atrophy (“SMA”) collaboration with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. (referred to collectively as “Roche”) and the Spinal Muscular Atrophy Foundation (“SMA Foundation”). The SMA program has one approved product, Evrysdi™ (risdiplam), which was approved by the United States Food and Drug Administration (“FDA”) in August 2020 for the treatment of SMA in adults and children two months and older and by the European Commission in March 2021 for the treatment of 5q SMA in patients two months and older with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. Evrysdi also received marketing authorization for the treatment of SMA in Brazil in October 2020 and Japan in June 2021. In addition to the Company’s SMA program, the Company’s splicing platform also includes PTC518, which is being developed for the treatment of Huntington’s disease (“HD”). The Company announced preliminary results from its ongoing Phase 1 study of PTC518 in healthy volunteers in April 2021 demonstrating dose-dependent lowering of huntingtin messenger ribonucleic acid levels and that PTC518 was well tolerated with no safety-related findings. The Company expects to announce results from additional cohorts for this Phase 1 study in the third quarter of 2021 and is planning to initiate a Phase 2 study of PTC518 by the end of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (“CNS”) including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (“AADC”) deficiency (“AADC deficiency”), a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. In January 2020, the Company submitted an MAA to the European Medicines Agency </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(“EMA”) for PTC-AADC for the treatment of AADC deficiency in the EEA, and the Company expects an opinion from the <span style="background-color:#ffffff;">Committee for Medicinal Products for Human Use (“CHMP”)</span> in the fourth quarter of 2021. The Company is also preparing a biologics license application (“BLA”) for PTC-AADC for the treatment of AADC deficiency in the United States and expects to submit a BLA to the FDA by the end of 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s Bio-e platform consists of small molecule compounds that target oxidoreductase enzymes that regulate oxidative stress and inflammatory pathways central to the pathology of a number of CNS diseases. The two most advanced molecules in the Company’s Bio-e platform are vatiquinone and PTC857. The Company initiated a registration-directed Phase 2/3 placebo-controlled trial of vatiquinone in children with mitochondrial disease and associated refractory epilepsy in the third quarter of 2020 and anticipates data from this trial to be available in the third quarter of 2022.  The Company also initiated a registration-directed Phase 3 trial of vatiquinone in children and young adults with Friedreich ataxia in the fourth quarter of 2020 and anticipates data from this trial to be available in 2023. In the second quarter of 2020, the Company initiated a Phase 1 trial in healthy volunteers to evaluate the safety and pharmacology of PTC857. This Phase 1 trial was recently completed and PTC857 was found to be well-tolerated with no reported serious adverse events while demonstrating predictable pharmacology. The Company expects to initiate a Phase 2 trial of PTC857 for amyotrophic lateral sclerosis in the first quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 29, 2020, the Company completed its acquisition of Censa Pharmaceuticals, Inc. (“Censa”) pursuant to an Agreement and Plan of Merger, dated as of May 5, 2020 (the "Censa Merger Agreement"), by and among the Company, Hydro Merger Sub, Inc., the Company’s wholly owned, indirect subsidiary, and, solely in its capacity as the representative, agent and attorney-in-fact of the securityholders of Censa, Shareholder Representative Services LLC (the "Censa Merger"). The transaction was accounted for as an asset acquisition. In connection with the Censa Merger, the Company acquired PTC923, an oral formulation of synthetic sepiapterin, a precursor to intracellular tetrahydrobiopterin, which is a critical enzymatic cofactor involved in metabolism and synthesis of numerous metabolic products. The Company expects to initiate a registration-directed Phase 3 trial for PTC923 for phenylketonuria (“PKU”) in the third quarter of 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company initiated a Phase 2/3 clinical trial evaluating the efficacy and safety of emvododstat, formerly known as PTC299, a dihydroorotate dehydrogenase inhibitor that the Company has also been developing in oncological indications, in patients hospitalized with COVID-19. The Company expects this trial to be completed by the end of 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission following reassessment by the EMA of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. This marketing authorization is further subject to the specific obligation to conduct and submit the results of a multi-center, randomized, double-blind, 18 month, placebo-controlled trial, followed by an 18 month open-label extension, according to an agreed protocol, in order to confirm the efficacy and safety of Translarna. The final report on the trial and open-label extension is to be submitted by the Company to the EMA by the end of the third quarter of 2022. The Company refers to the trial and open-label extension together as Study 041.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The marketing authorization in the EEA was last renewed in June 2021 and is effective, unless extended, through August 5, 2022. The renewal was based on the Company’s commitment to conduct Study 041 and the totality of the clinical data available from its trials and studies of Translarna for the treatment of nmDMD, including the safety and efficacy results of the Phase 2b and Phase 3 clinical trials. The primary efficacy endpoint was not achieved in either trial within the pre-specified level of statistical significance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Translarna is an investigational new drug in the United States. During the first quarter of 2017, the Company filed a New Drug Application (“NDA”) over protest with the FDA, for which the FDA granted a standard review. In October 2017, the Office of Drug Evaluation I of the FDA issued a complete response letter for the NDA, stating that it was unable to approve the application in its current form. In response, the Company filed a formal dispute resolution request with the Office of New Drugs of the FDA. In February 2018, the Office of New Drugs of the FDA denied the Company’s appeal of the Complete Response Letter. In its response, the Office of New Drugs recommended a possible path forward for the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ataluren NDA submission based on the accelerated approval pathway. This would involve a re-submission of an NDA containing the current data on effectiveness of ataluren with new data to be generated on dystrophin production in nmDMD patients’ muscles. The Company followed the FDA’s recommendation and collected, using newer technologies via procedures and methods that the Company designed, such dystrophin data in a new study, Study 045, and announced the results of Study 045 in February 2021. Study 045 did not meet its pre-specified primary endpoint. While the Company plans to discuss the Study 045 dystrophin results and the totality of existing clinical and real-world data with the FDA to determine if there is a potential path to approval based on these results and data, there is substantial risk that the FDA will determine that the results from the Company’s clinical trials and existing real-world data are not sufficient to support a marketing approval for Translarna for the treatment of nmDMD in the United States. The Company also expects to have data for Study 041 in the third quarter of 2022, and subject to a positive outcome in that study, the Company expects to re-submit the NDA at that time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of June 30, 2021, the Company had an accumulated deficit of approximately $1,821.1 million. The Company has financed its operations to date primarily through the private offerings in September 2019 of 1.50% convertible senior notes due 2026 and in August 2015 of 3.00% convertible senior notes due 2022 (collectively, the “Convertible Notes”) (see Note 9), public offerings of common stock in February 2014, October 2014, April 2018, January 2019, and September 2019, "at the market offerings" of its common stock, its initial public offering of common stock in June 2013, proceeds from a Royalty Purchase Agreement dated as of July 17, 2020, by and among the Company, RPI 2019 Intermediate Finance Trust (“RPI”), and, solely for the limited purposes set forth therein, Royalty Pharma PLC (the “Royalty Purchase Agreement”) (see Note 2), private placements of its convertible preferred stock, collaborations, bank and institutional lender debt, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company’s product candidates. Since 2014, the Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States, and since May 2017, the Company has generated revenue from net sales of Emflaza for the treatment of DMD in the United States. The Company has also relied on revenue associated with milestone and royalty payments from Roche pursuant to the License and Collaboration Agreement (the “SMA License Agreement”) dated as of November 23, 2011, by and among the Company, Roche and, for the limited purposes set forth therein, the SMA Foundation, under its SMA program. The Company expects that cash flows from the sales of its products, together with the Company’s cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months.  </p>
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1821100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, royalty revenue, certain accruals related to the Company’s research and development expenses, valuation procedures for liability for sale of future royalties, valuation procedures for convertible notes, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p>
CY2021Q2 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
7500000
ptct Termforletterofcredit
Termforletterofcredit
P5Y
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
177347000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
208812000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
7500000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
7500000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
184847000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
216312000
CY2021Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2021Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2021Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
687000
CY2020Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
824000
CY2021Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
8840000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
8745000
CY2021Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
6914000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
9128000
CY2021Q2 us-gaap Inventory Net
InventoryNet
16441000
CY2020Q4 us-gaap Inventory Net
InventoryNet
18697000
CY2021Q2 us-gaap Inventory Write Down
InventoryWriteDown
300000
us-gaap Inventory Write Down
InventoryWriteDown
1700000
us-gaap Inventory Write Down
InventoryWriteDown
200000
CY2020Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
CY2021Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
CY2021Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
100000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
100000
CY2020Q3 ptct Assigned Royalty Payment Retained Percentage
AssignedRoyaltyPaymentRetainedPercentage
0.57067
CY2021Q2 ptct Revenue Recognition Milestone Potential Achievements
RevenueRecognitionMilestonePotentialAchievements
335000000.0
ptct Deferred Payroll Tax Liability Cares Act
DeferredPayrollTaxLiabilityCaresAct
2500000
CY2017Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021Q2 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
122000000.0
CY2021Q2 ptct Number Of Operating Leases
NumberOfOperatingLeases
3
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
5200000
CY2020Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
2600000
us-gaap Operating Lease Expense
OperatingLeaseExpense
10600000
us-gaap Operating Lease Expense
OperatingLeaseExpense
5000000.0
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
4115000
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
1970000
us-gaap Operating Lease Cost
OperatingLeaseCost
8219000
us-gaap Operating Lease Cost
OperatingLeaseCost
4089000
CY2021Q2 us-gaap Variable Lease Cost
VariableLeaseCost
993000
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
507000
us-gaap Variable Lease Cost
VariableLeaseCost
2087000
us-gaap Variable Lease Cost
VariableLeaseCost
734000
CY2021Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
119000
CY2020Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
88000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
283000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
165000
CY2021Q2 ptct Lease Cost Excluding Finance Lease Costs
LeaseCostExcludingFinanceLeaseCosts
5227000
CY2020Q2 ptct Lease Cost Excluding Finance Lease Costs
LeaseCostExcludingFinanceLeaseCosts
2565000
ptct Lease Cost Excluding Finance Lease Costs
LeaseCostExcludingFinanceLeaseCosts
10589000
ptct Lease Cost Excluding Finance Lease Costs
LeaseCostExcludingFinanceLeaseCosts
4988000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
80694000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
84410000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7335000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7465000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
76425000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
79499000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
83760000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
86964000
CY2021Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2121000
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1276000
CY2021Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
20053000
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
23053000
CY2021Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
22174000
CY2020Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
24329000
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y2M8D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y5M26D
CY2021Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0890
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0886
CY2021Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P11Y6M
CY2020Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P12Y
CY2021Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0780
CY2020Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0780
us-gaap Operating Lease Payments
OperatingLeasePayments
6816000
us-gaap Operating Lease Payments
OperatingLeasePayments
3414000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2224000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
15000000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
776000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
13000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
18117000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
41212000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
6892000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
13314000
CY2021Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
3000000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
12862000
CY2021Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
3000000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
12161000
CY2021Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
3000000
CY2021Q2 ptct Lessee Operating Lease Liability To Be Paid Year Four And After
LesseeOperatingLeaseLiabilityToBePaidYearFourAndAfter
92003000
CY2021Q2 ptct Finance Lease Liability To Be Paid Year Four And After
FinanceLeaseLiabilityToBePaidYearFourAndAfter
24000000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
137232000
CY2021Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
33000000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
53472000
CY2021Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
10826000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
83760000
CY2021Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
22174000
CY2021Q2 ptct Clearpoint Equity Investment Fvni Unrealized Gain Loss
ClearpointEquityInvestmentFvniUnrealizedGainLoss
-2700000
ptct Clearpoint Equity Investment Fvni Unrealized Gain Loss
ClearpointEquityInvestmentFvniUnrealizedGainLoss
4100000
CY2020Q2 ptct Clearpoint Equity Investment Fvni Unrealized Gain Loss
ClearpointEquityInvestmentFvniUnrealizedGainLoss
-100000
ptct Clearpoint Equity Investment Fvni Unrealized Gain Loss
ClearpointEquityInvestmentFvniUnrealizedGainLoss
-1600000
CY2021Q2 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
24700000
CY2020Q4 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
20500000
CY2020Q1 ptct Payments To Acquire Convertible Debt Investment
PaymentsToAcquireConvertibleDebtInvestment
10000000.0
CY2020Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
6.00
CY2020Q1 ptct Debt Instrument Convertible Period
DebtInstrumentConvertiblePeriod
P5Y
CY2021Q2 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
3500000
us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
4300000
CY2020Q2 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
2100000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
700000
CY2021Q2 ptct Convertible Debt Security
ConvertibleDebtSecurity
33600000
CY2020Q4 ptct Convertible Debt Security
ConvertibleDebtSecurity
29300000
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
200000000.0
CY2021Q1 ptct Number Of Mutual Funds Invested In
NumberOfMutualFundsInvestedIn
2
CY2021Q2 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
1000000.0
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
700000
CY2021Q2 ptct Fair Value Assets Transfers Between Level1 Level2 And Level3 Amount
FairValueAssetsTransfersBetweenLevel1Level2AndLevel3Amount
0
CY2020Q4 ptct Fair Value Assets Transfers Between Level1 Level2 And Level3 Amount
FairValueAssetsTransfersBetweenLevel1Level2AndLevel3Amount
0
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
50000
CY2021Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
568509000
CY2021Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
581000
CY2021Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
569040000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
892938000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1975000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
75000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
894838000
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Writeoff
DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff
0
CY2021Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Writeoff
DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
CY2020Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
CY2021Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Period Increase Decrease
DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease
0
CY2021Q2 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0.0
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
700000
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
200000
CY2020Q2 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
200000
CY2021Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
50000
CY2021Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
117895000
CY2021Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
50000
CY2021Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
117895000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
75000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
260970000
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
75000
CY2020Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
260970000
CY2021Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
410553000
CY2021Q2 ptct Available For Sale Securities Debt Maturities Over One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
158487000
CY2020Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
588863000
CY2020Q4 ptct Available For Sale Securities Debt Maturities Over One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue
305975000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
31595000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
53291000
CY2021Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
618000
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4315000
CY2021Q2 ptct Accrued Consulting And Contracted Research Current
AccruedConsultingAndContractedResearchCurrent
25848000
CY2020Q4 ptct Accrued Consulting And Contracted Research Current
AccruedConsultingAndContractedResearchCurrent
18250000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4975000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3614000
CY2021Q2 ptct Sales Allowance And Other Related Costs
SalesAllowanceAndOtherRelatedCosts
59431000
CY2020Q4 ptct Sales Allowance And Other Related Costs
SalesAllowanceAndOtherRelatedCosts
54327000
CY2021Q2 ptct Sales Rebates Current
SalesRebatesCurrent
58351000
CY2020Q4 ptct Sales Rebates Current
SalesRebatesCurrent
63774000
CY2021Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
27457000
CY2020Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
16575000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
20820000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
18665000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6826000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9357000
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
235921000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
242168000
CY2020Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
106309
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
368514
CY2020Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
5400000
us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
19000000.0
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
0
CY2021Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
0
us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
0
CY2021Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
0
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-118370000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-181427000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-247012000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-294114000
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
70414632
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
65150780
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
70302241
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
63769958
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.68
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.78
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.51
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.61
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12563890
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12891606
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25699000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16910000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
51406000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32130000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
252500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10M17D
CY2020Q3 ptct Proceeds From Sale Of Future Royalties
ProceedsFromSaleOfFutureRoyalties
650000000.0
CY2020Q3 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.110
CY2020Q4 ptct Liability Sale Of Future Royalties
LiabilitySaleOfFutureRoyalties
679762000
ptct Liability Sale Of Future Royalties Royalty Revenue Payable
LiabilitySaleOfFutureRoyaltiesRoyaltyRevenuePayable
8681000
ptct Liability Sale Of Future Royalties Interest Expense
LiabilitySaleOfFutureRoyaltiesInterestExpense
38083000
CY2021Q2 ptct Liability Sale Of Future Royalties
LiabilitySaleOfFutureRoyalties
709164000
CY2021Q2 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.115
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q2 ptct Numberofdistributors
Numberofdistributors
2
CY2020Q2 ptct Numberofdistributors
Numberofdistributors
2
ptct Numberofdistributors
Numberofdistributors
2
ptct Numberofdistributors
Numberofdistributors
3
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
4200000
CY2021Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1900000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
4000000.0
CY2020Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2000000.0
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
4000000.0
CY2020Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
4200000
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
12800000
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8700000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24000000.0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
16700000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
25496000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
50992000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
50992000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
8482000
CY2021Q2 ptct Finite Lived Intangible Assets Amortization Expense Year Four And Thereafter
FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndThereafter
4617000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
140579000
us-gaap Indefinitelived Intangible Assets Acquired
IndefinitelivedIntangibleAssetsAcquired
576500000
us-gaap Indefinite Lived Intangible Assets Period Increase Decrease
IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease
0
CY2018Q3 us-gaap Goodwill
Goodwill
82300000
us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0
CY2021Q2 us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0

Files In Submission

Name View Source Status
0001070081-21-000029-index-headers.html Edgar Link pending
0001070081-21-000029-index.html Edgar Link pending
0001070081-21-000029.txt Edgar Link pending
0001070081-21-000029-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ptct-20210630.xsd Edgar Link pending
ptct-20210630ex3115d3fd5.htm Edgar Link pending
ptct-20210630ex312113d92.htm Edgar Link pending
ptct-20210630ex31290f854.htm Edgar Link pending
ptct-20210630ex3216adcea.htm Edgar Link pending
ptct-20210630ex32256b5b5.htm Edgar Link pending
ptct-20210630x10q.htm Edgar Link pending
ptct-20210630x10q_htm.xml Edgar Link completed
ptct-20210630_cal.xml Edgar Link unprocessable
ptct-20210630_def.xml Edgar Link unprocessable
ptct-20210630_lab.xml Edgar Link unprocessable
ptct-20210630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending